Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1947 1
1952 1
1953 1
1954 7
1955 2
1956 4
1958 4
1959 1
1964 6
1965 10
1966 23
1967 28
1968 25
1969 31
1970 55
1971 56
1972 46
1973 57
1974 64
1975 70
1976 33
1977 38
1978 42
1979 30
1980 29
1981 11
1982 34
1983 22
1984 19
1985 23
1986 43
1987 184
1988 125
1989 133
1990 222
1991 233
1992 171
1993 231
1994 290
1995 258
1996 262
1997 314
1998 257
1999 286
2000 320
2001 324
2002 340
2003 325
2004 336
2005 298
2006 322
2007 305
2008 264
2009 281
2010 286
2011 267
2012 255
2013 252
2014 240
2015 240
2016 238
2017 212
2018 189
2019 205
2020 231
2021 195
2022 217
2023 219
2024 66

Text availability

Article attribute

Article type

Publication date

Search Results

9,544 results

Results by year

Filters applied: . Clear all
Page 1
Primary CNS Lymphoma.
Grommes C, DeAngelis LM. Grommes C, et al. J Clin Oncol. 2017 Jul 20;35(21):2410-2418. doi: 10.1200/JCO.2017.72.7602. Epub 2017 Jun 22. J Clin Oncol. 2017. PMID: 28640701 Free PMC article. Review.
Primary CNS lymphoma (PCNSL) is a rare form of extranodal non-Hodgkin lymphoma that is typically confined to the brain, eyes, and cerebrospinal fluid without evidence of systemic spread. ...To our knowledge, no randomized trial has been conducte …
Primary CNS lymphoma (PCNSL) is a rare form of extranodal non-Hodgkin lymphoma that is typically confined to the brain, …
Revised response criteria for malignant lymphoma.
Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V; International Harmonization Project on Lymphoma. Cheson BD, et al. J Clin Oncol. 2007 Feb 10;25(5):579-86. doi: 10.1200/JCO.2006.09.2403. Epub 2007 Jan 22. J Clin Oncol. 2007. PMID: 17242396
PURPOSE: Standardized response criteria are needed to interpret and compare clinical trials and for approval of new therapeutic agents by regulatory agencies. ...
PURPOSE: Standardized response criteria are needed to interpret and compare clinical trials and for approval of new therapeutic agent …
Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling.
Hosseini I, Gadkar K, Stefanich E, Li CC, Sun LL, Chu YW, Ramanujan S. Hosseini I, et al. NPJ Syst Biol Appl. 2020 Aug 28;6(1):28. doi: 10.1038/s41540-020-00145-7. NPJ Syst Biol Appl. 2020. PMID: 32859946 Free PMC article.
Mosunetuzumab, a T-cell dependent bispecific antibody that binds CD3 and CD20 to drive T-cell mediated B-cell killing, is currently being tested in non-Hodgkin lymphoma. However, potent immune stimulation with T-cell directed therapies poses the risk of cytok …
Mosunetuzumab, a T-cell dependent bispecific antibody that binds CD3 and CD20 to drive T-cell mediated B-cell killing, is currently being te …
Copanlisib in the treatment of non-Hodgkin lymphoma.
Narkhede M, Cheson BD. Narkhede M, et al. Future Oncol. 2020 Sep;16(26):1947-1955. doi: 10.2217/fon-2020-0195. Epub 2020 Jul 13. Future Oncol. 2020. PMID: 32658557 Review.
B-cell receptor signaling is important in the pathogenesis of non-Hodgkin lymphoma. The PI3K pathway is activated by B-cell receptor signaling. ...
B-cell receptor signaling is important in the pathogenesis of non-Hodgkin lymphoma. The PI3K pathway is activated by B- …
Subcutaneous epcoritamab monotherapy in Japanese adults with relapsed/refractory diffuse large B-cell lymphoma.
Izutsu K, Kumode T, Yuda J, Nagai H, Mishima Y, Suehiro Y, Yamamoto K, Fujisaki T, Ishitsuka K, Ishizawa K, Ikezoe T, Nishikori M, Akahane D, Fujita J, Dinh M, Soong D, Noguchi H, Buchbjerg JK, Favaro E, Fukuhara N. Izutsu K, et al. Cancer Sci. 2023 Dec;114(12):4643-4653. doi: 10.1111/cas.15996. Epub 2023 Nov 3. Cancer Sci. 2023. PMID: 37921363 Free PMC article.
Epcoritamab is a subcutaneously administered CD3xCD20 bispecific Ab that showed deep, durable responses with a manageable safety profile in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in the global multicenter pivotal phase II trial EPC …
Epcoritamab is a subcutaneously administered CD3xCD20 bispecific Ab that showed deep, durable responses with a manageable safety profile in …
Asparaginase revisited.
van den Berg H. van den Berg H. Leuk Lymphoma. 2011 Feb;52(2):168-78. doi: 10.3109/10428194.2010.537796. Leuk Lymphoma. 2011. PMID: 21281233 Review.
Bexxar (Corixa/GlaxoSmithKline).
Cheson B. Cheson B. Curr Opin Investig Drugs. 2002 Jan;3(1):165-70. Curr Opin Investig Drugs. 2002. PMID: 12054068 Review.
Non-Hodgkin's lymphoma: the old and the new.
Cabanillas F. Cabanillas F. Clin Lymphoma Myeloma Leuk. 2011 Jun;11 Suppl 1:S87-90. doi: 10.1016/j.clml.2011.03.029. Epub 2011 Apr 28. Clin Lymphoma Myeloma Leuk. 2011. PMID: 22035756 Review.
During the past decade we have witnessed a number of changes in the field of non-Hodgkin lymphoma (NHL), including new entities added to the classification as well as a better understanding of the biology of diffuse large B-cell lymphoma (DLBCL). ...Overlappi …
During the past decade we have witnessed a number of changes in the field of non-Hodgkin lymphoma (NHL), including new …
Primary testicular lymphoma.
Cheah CY, Wirth A, Seymour JF. Cheah CY, et al. Blood. 2014 Jan 23;123(4):486-93. doi: 10.1182/blood-2013-10-530659. Epub 2013 Nov 26. Blood. 2014. PMID: 24282217 Free article. Review.
The vast majority of cases are histologically diffuse large B-cell lymphoma, but rarer subtypes are clinically important and must be recognized. In this review, we discuss the incidence, clinical presentation, and prognostic factors of PTL and present a summary of the rece …
The vast majority of cases are histologically diffuse large B-cell lymphoma, but rarer subtypes are clinically important and must be recogni …
Advancing radioimmunotherapy and its future role in non-Hodgkin lymphoma.
Reagan PM, Friedberg JW. Reagan PM, et al. Future Oncol. 2015;11(10):1543-53. doi: 10.2217/fon.15.1. Future Oncol. 2015. PMID: 25963431 Review.
Radioimmunotherapy is an effective treatment modality with an acceptable toxicity profile in both indolent B-cell non-Hodgkin lymphoma and histologic transformation. Its ease of administration from a patient's perspective sets it apart from chemoimmunotherapy …
Radioimmunotherapy is an effective treatment modality with an acceptable toxicity profile in both indolent B-cell non-Hodgkin …
9,544 results